ATAI Life Sciences NV ATAI:NASDAQ

RT Quote | Last NYSE, VOL From CTA | USD
Last | 2:26 PM EST
1.82UNCH (UNCH)
Volume
876,027
52 week range
1.45 - 6.32
Loading...
  • Open1.81
  • Day High1.84
  • Day Low1.77
  • Prev Close1.82
  • 52 Week High6.32
  • 52 Week High Date02/16/22
  • 52 Week Low1.45
  • 52 Week Low Date01/06/23

Key Stats

  • Market Cap301.893M
  • Shares Out165.88M
  • 10 Day Average Volume1.80M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-31.27

KEY STATS

  • Open1.81
  • Day High1.84
  • Day Low1.77
  • Prev Close1.82
  • 52 Week High6.32
  • 52 Week High Date02/16/22
  • 52 Week Low1.45
  • 52 Week Low Date01/06/23
  • Market Cap301.893M
  • Shares Out165.88M
  • 10 Day Average Volume1.80M
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-31.27

RATIOS/PROFITABILITY

  • EPS (TTM)-1.29
  • P/E (TTM)-1.41
  • Fwd P/E (NTM)-1.90
  • EBITDA (TTM)-145.35M
  • ROE (TTM)-52.86%
  • Revenue (TTM)423,999.995
  • Gross Margin (TTM)-
  • Net Margin (TTM)-33,076.89%
  • Debt To Equity (MRQ)5.18%

EVENTS

  • Earnings Date03/30/2023(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On ATAI Life Sciences NV

 

Profile

MORE
ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The Company engages in developing various treatments that focuses on various mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002...
Florian Brand
Chief Executive Officer, Co-Founder
Greg Weaver
Chief Financial Officer
Address
Wallstrasse 16
Berlin
10179
Germany

Top Peers

SYMBOLLASTCHG%CHG
TERN
Terns Pharmaceuticals Inc
7.87-0.18-2.24%
AURA
Aura Biosciences Inc
9.99-0.05-0.50%
ANNX
Annexon Inc
7.38+0.07+0.89%
RANI
Rani Therapeutics Holdings Inc
5.62-0.21-3.60%
CABA
Cabaletta Bio Inc
11.67+1.22+11.67%